Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$35.14 USD

35.14
1,123,278

-1.02 (-2.82%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $35.07 -0.07 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Techne (TECH) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

by Zacks Equity Research

CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the FDA to provide time for reviewing a REMS submission made at the agency's request.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of 3.55% and 26.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

by Zacks Equity Research

Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.

Zacks Equity Research

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

by Zacks Equity Research

Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

Zacks Equity Research

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

by Zacks Equity Research

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

by Zacks Equity Research

CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -3.28% and 14.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

by Zacks Equity Research

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

by Zacks Equity Research

SAGE and AKRO are up this week on regulatory and pipeline updates.

Zacks Equity Research

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

by Zacks Equity Research

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Zacks Equity Research

Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?

by Zacks Equity Research

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Cytokinetics Initiates Confirmatory Study on Heart Failure Drug

by Zacks Equity Research

CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.

Zacks Equity Research

FDA Accepts Cytokinetics' Application for Cardiovascular Drug

by Zacks Equity Research

CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.

Zacks Equity Research

FDA Accepts Bayer's Application for Label Expansion of Nubeqa

by Zacks Equity Research

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

Zacks Equity Research

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

by Zacks Equity Research

BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.09% and 54.87%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -28.43% and 98.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday

by Zacks Equity Research

Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?